fluorodeoxyglucose f18 has been researched along with (5-(2,4-bis((3s)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guichard, SM; Keen, HG; Logie, A; Maynard, J; Odedra, R; Ricketts, SA; Shannon, AM; Wedge, SR | 1 |
1 other study(ies) available for fluorodeoxyglucose f18 and (5-(2,4-bis((3s)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol
| Article | Year |
|---|---|
Examining changes in [18 F]FDG and [18 F]FLT uptake in U87-MG glioma xenografts as early response biomarkers to treatment with the dual mTOR1/2 inhibitor AZD8055.
Topics: Animals; Biomarkers, Tumor; Brain Neoplasms; Female; Fluorodeoxyglucose F18; Glioma; Humans; Mice; Mice, Nude; Morpholines; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor Receptor-1 | 2014 |